Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
• MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance